Patiromer for the management of hyperkalaemia in patients receiving renin–angiotensin–aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any...

Full description

Bibliographic Details
Main Author: Butler, Javed (author)
Other Authors: Anker, Stefan D. (author), Siddiqi, Tariq Jamal (author), Coats, Andrew J. S. (author), Dorigotti, Fabio (author), Filippatos, Gerasimos (author), Friede, Tim (author), Göhring, Udo‐Michael (author), Kosiborod, Mikhail N. (author), Lund, Lars H. (author), Metra, Marco (author), Moreno Quinn, Carol (author), Piña, Ileana L. (author), Pinto, Fausto J. (author), Rossignol, Patrick (author), Szecsödy, Peter (author), Van Der Meer, Peter (author), Weir, Matthew (author), Pitt, Bertram (author)
Format: article
Language:eng
Published: 2022
Subjects:
Adherence
Heart failure
Hyperkalaemia
Mineralocorticoid receptor antagonists
Patiromer
Potassium
Renin-angiotensin-aldosterone system inhibitors
Trial design
Online Access:http://hdl.handle.net/10451/50788
Country:Portugal
Oai:oai:repositorio.ul.pt:10451/50788

Internet

http://hdl.handle.net/10451/50788

Similar Items